MedTrace Logo

TRIMBOW® and RELVAR® on Lung Stiffness Reduction Assessed Through Forced Oscillation Technique in Patients With COPD

NCT04671355 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2022-02-03

No results posted yet for this study

Summary

Efficacy of TRIMBOW® pMDI and RELVAR® ELLIPTA® DPI on lung stiffness reduction assessed through area under the reactance curve (AX) using oscillometry in chronic obstructive pulmonary disease (COPD).

Conditions

Interventions

DRUG

Beclometasone Dipropionate / Formoterol Fumarate / Glycopyrronium 100/6/10 mcg

Pressurized metered dose inhaler

DRUG

Fluticasone Furoate / Vilanterol Trifenatate 100/25 mcg

Dry powder inhaler

Sponsors & Collaborators

  • Chiesi Farmaceutici S.p.A.

    lead INDUSTRY

Principal Investigators

  • Brian Lipworth, MD · Ninewells Hospital, University of Dundee, Scotland, UK

  • Catherine Jackson, MD · University of Central Lancashire, Burnley, UK

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-04
Primary Completion
2021-12-22
Completion
2022-02-18

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04671355 on ClinicalTrials.gov